louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02190734: Pushing Behaviors in Individuals Post-stroke
Official title: Inpatient Rehabilitation Treatments and Effect on Pushing Behaviors in Individuals Post-stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: Stroke
Pusher Syndrome
Lateropulsion
Pushing Behaviors
Burke Lateropulsion Scale
Lead sponsor: Shirley Ryan AbilityLab
Sponsor class: OTHER
First posted: 2014-07-15
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Some individuals demonstrate pushing behaviors after having a stroke. The purpose of this study is to see if there are immediate changes in pushing behaviors in individuals who have had a stroke before and after sitting in a wheelchair, walking on the treadmill, and walking overground.

The investigators do not think there will be a change with sitting in the wheelchair, but the investigators think there may be an improvement in pushing behaviors after walking training.

Detailed description: The study population of interest is primarily individuals in inpatient rehabilitation.

Eligibility criteria: Inclusion Criteria:

* score \>0 in each subsection of the Scale for Contraversive Pushing
* admitted to the Rehabilitation Institute of Chicago inpatient rehabilitation setting
* stroke within previous 180 days
* consent to participate in the study
* ambulating greater than 150' at a time prior to stroke

Exclusion Criteria:

* other neurologic diagnoses
* weight bearing precautions, orthopedic injuries, or other medical co-morbidities that prevent adherence to the study protocol

Primary outcomes:
measure: Burke Lateropulsion Scale
timeFrame: Before and after each of 3 treatment sessions (3 separate days) over a maximum of a 10 day period
Secondary outcomes:
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Rehabilitation Hospital of the Pacific
state: Hawaii
city: Chicago
country: United States
facility: Rehabilitation Institute of Chicago
state: Illinois
Study officials:
affiliation: Rehabilitation Institute of Chicago, University of Illinois at Chicago
name: T. George Hornby, PT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03051334: Ascending Aortic Dilation in BiAV After TAVR
Official title: Changes in Ascending Aorta Size After Transcatheter Aortic Valve Replacement in Severe Bicuspid Aortic Stenosis: A Pilot Study With Echocardiographic Follow-up
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Aortic Valve Stenosis
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-02-13
Enrollment: 100
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Severe AS who underwent TAVR

Brief summary: This study sought to evaluate changes in ascending aorta size after transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BiAV) compared with patients with tricuspid aortic valve (TAV).

Detailed description: The growth rate of ascending aorta was calculated as annual growth rate using baseline and the last echocardiography. The difference in ascending aorta growth rates between the two groups (BiAV and TAV) were analyzed by independent t-test.

Eligibility criteria: Inclusion Criteria:

* Severe AS who underwent TAVR

Exclusion Criteria:

* ascending aorta more than 50mm

Primary outcomes:
measure: changes in dimension of ascending aorta
timeFrame: baseline and 1year after TAVR
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT01519934: A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
Official title: Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Laxity
Wrinkles
Keywords: Ulthera® System
Ultherapy™ Treatment
Ulthera, Inc.
Ultrasound treatment for skin tightening
Lead sponsor: Merz North America, Inc.
Sponsor class: INDUSTRY
First posted: 2012-01-27
Enrollment: 48
Sex: ALL
Minimum age (years): 25
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of males and females from the investigator's practice between 25 and 85 years of age, who have received an Ultherapy™ treatment on or prior to October 1, 2011, who had pre-treatment baseline photographs taken, and who have chosen to participate in this clinical trial.

Brief summary: Up to 120 subjects within the study site's practice who have already had an Ultherapy™ treatment to the face and neck will be enrolled to monitor treatment effectiveness. Follow-up visits will occur at 90 and 180 days post-treatment. Study images will be obtained at each follow-up visit.

Detailed description: This is a retrospective, single-center clinical trial to evaluate the efficacy of the Ulthera System for non-invasive treatment of skin texture and laxity six months after treatment. Global Aesthetic Improvement Scale scores, patient satisfaction questionnaires, and quality of life questionnaires will be obtained.

Eligibility criteria: Inclusion Criteria:

* Male or female, age 25-85 years.
* Subject in good health.
* Received Ultherapy™ treatment prior to or on October 1, 2011, and must have had pre-treatment baseline photographs taken.
* Willingness and ability to comply with protocol requirements, including returning for follow-up visits.
* Absence of physical or psychological conditions unacceptable to the investigator.

Exclusion Criteria:

* Presence of an active systemic or local skin disease that may affect wound healing.
* Significant scarring in areas treated.
* Open wounds or lesions in the areas treated.
* Severe or cystic acne on the areas treated.
* Inability to understand the protocol or to give informed consent.

Primary outcomes:
measure: Improvement in Overall Lifting and Tightening of the Skin
timeFrame: Baseline to 180 days post-treatment
Secondary outcomes:
measure: Overall Aesthetic Improvement
timeFrame: Baseline to 180 days post-treatment
measure: Subject Perception of Age
timeFrame: Baseline to 180 days post-treatment
measure: Patient Satisfaction
timeFrame: 180 days post-treatment
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Dermatology Cosmetic Laser Associates
state: California
Study officials:
affiliation: Dermatology Cosmetic Laser Associates
name: Mitchel Goldman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03681834: Multi-center Register for the Use of the Cor-Knot® Automated Knotting System in Heart Valve Surgery
Official title: Multi-center Register for the Use of the Cor-Knot® Automated Knotting System in Heart Valve Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vascular Surgery
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2018-09-24
Enrollment: 364
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients requiring valve surgery

Brief summary: The Cor-Knot® device is an automated knotting system for valve sutures and prosthetic rings used for more than a year during valve replacements and annuloplasties in cardiac surgery. It reduces the time spent knotting the threads fixing the prosthesis and thus reduces aortic clamping and extracorporeal circulation times. The originality of the project is based on the absence of national multi-rate data collection on the effectiveness and safety of the Cor-Knot® knotting device.


Eligibility criteria: Inclusion Criteria:

* programmed minimally invasive surgery for:

  * aortic valve replacement
  * mitral valve replacement
  * mitral valve plastic surgery
* adult patient

Exclusion Criteria:

* emergency surgery

Primary outcomes:
measure: Presence of periprosthetic leak around the prosthetic rings as determined during physical examination (rated yes/no )
timeFrame: Day 30
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourogne
Study officials:
References:
Clinical trial NCT00752934: Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Cerebral Palsy
Keywords: nursing homes
children
ages 1-18 years
spastic quadriplegia
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2008-09-16
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Baclofen is a drug that reduces the muscle stiffness. In disabled children that have very stiff muscles, the stiffness and secondary changes in the joints may cause discomfort and pain. In this study we will check if treatment with Baclofen reduces pain in disabled children with stiff muscles.


Eligibility criteria: Inclusion Criteria:

* Cerebral palsy nursing homes children ages 1-18 years spastic quadriplegia

Exclusion Criteria:

* active epilepsy severe truncal hypotonia

Primary outcomes:
measure: care and comport questionnaires
timeFrame: 28 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Saare Zedek Medical Center
Study officials:
References:
Clinical trial NCT01822834: Bronchiectasis and NTM Research Registry
Official title: Bronchiectasis and NTM Research Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non-CF Bronchiectasis
Nontuberculosis Mycobacteria (NTM)
Lead sponsor: COPD Foundation
Sponsor class: OTHER
First posted: 2013-04-02
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over the age of 18 with non-CF Bronchiectasis and/or Nontuberculosis Mycobacteria (NTM).

Brief summary: The Bronchiectasis Research Registry is a consolidated database of non-cystic fibrosis (non-CF) Bronchiectasis and Nontuberculosis Mycobacteria (NTM) patients from multiple clinical institutions.

Detailed description: The Bronchiectasis Research Registry is a consolidated database of non-cystic fibrosis (non-CF) Bronchiectasis and Nontuberculosis Mycobacteria (NTM) patients from multiple clinical institutions. The goal of the Bronchiectasis Research Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of NTM and non-CF Bronchiectasis, a progressive, non-curable disease of the lungs, which afflicts thousands of patients. The Registry will also be used to provide better insight into the study of the different types of Bronchiectasis, as well as the pathophysiology of the disorder. In 2012, in collaboration with NTM Info and Research, Inc (NTMir) and the consortium members, the COPD Foundation expanded the Bronchiectasis Research Registry to enroll patients with "non tuberculous mycobacteria (NTM) only". Prior to this time, the registry included individuals with Bronchiectasis, with or without NTM.

Eligibility criteria: Inclusion Criteria:

* Over the age of 18
* non-CF Bronchiectasis
* Nontuberculosis Mycobacteria (NTM)

Exclusion Criteria:

* Under the age of 18
* CF Bronchiectasis

Primary outcomes:
measure: Patient Recruitment and Data analysis
timeFrame: December 2050
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: COPD Foundation
state: District of Columbia
Study officials:
References:
Clinical trial NCT04373434: Healthy Homes/Healthy Families (HH/HF) Intervention in 2-1-1 Callers
Official title: A Hybrid Effectiveness-Implementation Study on Weight Gain Prevention Among 2-1-1 Callers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weight Change, Body
Keywords: Weight Gain Prevention
Cancer Prevention
Chronic Conditions
Obesity
Healthy Eating
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2020-05-04
Enrollment: 512
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This trial will evaluate a healthy eating and weight gain prevention intervention for delivery through calls to the 2-1-1 number.

Detailed description: It is now well-established that obesity and excess weight increase the risk of cancer (i.e., colorectal and post-menopausal breast cancer), as well as other chronic diseases including diabetes, stroke, coronary heart disease, and arthritis. The World Cancer Research Fund and the American Institute for Cancer Research state "maintenance of a healthy weight throughout life may be one of the most important ways to protect against cancer". Unfortunately, adults generally gain weight as they age.

Healthy Homes/Healthy Families (HH/HF) Intervention involves a tailored home environment profile and a health coach working with participants to select and implement a series of healthy actions to create a home environment more supportive of healthy eating and physical activity.

The Federal Communications Commission (FCC) designated 2-1-1 as the 3-digit number to call for information and referrals to social services and other assistance in the United States. This study will evaluate a healthy eating and weight gain prevention intervention for delivery through 2-1-1 calls.

Eligibility criteria: Inclusion Criteria:

* 18 to 70 years of age
* able to speak English
* self-report BMI of 20 and above

Exclusion Criteria:

* pregnant women
* only one member per household will be enrolled

Primary outcomes:
measure: Change in United States Department of Agriculture (USDA) Healthy Eating Index (HEI)
timeFrame: Baseline, Month 4, Month 9
Secondary outcomes:
measure: Change in Kcal per day intake
timeFrame: Baseline, Month 4, Month 9
measure: Change in self-reported weight
timeFrame: Baseline, Month 4, Month 9
measure: Changes to food environment
timeFrame: Baseline, Month 4, Month 9
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University, Rollins School of Public Health
state: Georgia
Study officials:
affiliation: Emory University
name: Michelle Kegler, DrPH/MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01639716: Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers
Official title: Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphoma
Keywords: Survey, interleukin status
Lead sponsor: Guler, Nil, M.D.
Sponsor class: INDIV
First posted: 2012-07-13
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 31 newly diagnosed non hodgkin lymphoma and 27 healthy controls. We studied IL-10 and IL-4 in lymphoma group and healthy group and observed patients till end of study. We analised survival. We compared with IL-4 and IL-10 levels with prognostic factors.

Brief summary: The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.


Eligibility criteria: Inclusion Criteria:

* newly diagnosed non hodgkin lymphoma
* Diffuse large B cell lymphoma and T cell lymphoma patients

Exclusion Criteria:

* under 18 age
* parasitosis
* allergic status

Primary outcomes:
measure: Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma
timeFrame: This study ended within 13 months
Secondary outcomes:
measure: survey as months
timeFrame: During study which was 13 months
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ondokuz Mayis University Medical School
state: Atakum
Study officials:
name: Nil Guler, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: ONDOKUZ MAYİS UNİVERSİTY, SCHOOL OF MEDİCİNE
name: Nil Guler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00829816: Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
Official title: A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer's Disease
Keywords: Alzheimers disease
donepezil
memantine
Lead sponsor: Medivation, Inc.
Sponsor class: INDUSTRY
First posted: 2009-01-27
Enrollment: 46
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.


Eligibility criteria: Inclusion Criteria:

* Alzheimer's disease
* On Memantine
* Caregiver who is willing to accompany the patient to all clinic visits

Exclusion Criteria:

* Unstable medical illnesses or significant hepatic or renal disease
* Other primary psychiatric or neurological disorders

Primary outcomes:
measure: To assess the safety and tolerability of orally administered dimebon in patients with Alzheimer's disease (AD) on a stable dose and regimen of memantine, or memantine plus donepezil.
timeFrame: up to 28 days
Secondary outcomes:
measure: To assess the steady-state pharmacokinetics (PK) of orally-administered dimebon in patients with AD on a stable dose and regimen of memantine, or memantine plus donepezil.
timeFrame: up to 28 days
Other outcomes:
Locations:
city: Los Alamitos
country: United States
state: California
city: National City
country: United States
state: California
city: Delray Beach
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
Study officials:
References:
Clinical trial NCT00762216: Rotational Stability of the AcrySof® Toric
Official title: Rotational Stability of the AcrySof® Toric
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Keywords: Cataract
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2008-09-30
Enrollment: 71
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the rotational stability and the residual refractive cylinder and patient reported outcomes of the AcrySof Toric intraocular lens after unilateral or bilateral implantation.


Eligibility criteria: Inclusion Criteria:

* Monolateral or bilateral cataracts
* anticipated intraocular lens (IOL) power of +10 Diopters (D) \~ +25D
* 0.75 \~ 2.0 D of astigmatism measured preoperatively by Keratometry readings
* able to sign the informed consent, to comply with scheduled visits and other study procedures

Exclusion Criteria:

* Preoperative ocular pathology
* previous intraocular or corneal surgery
* an increased risk for complications which could require vitreoretinal surgery
* corneal irregularities
* corneal opacities
* current contact lens usage
* uncontrolled diabetes

Primary outcomes:
measure: Rotational Stability
timeFrame: 6 Months post-surgery
Secondary outcomes:
measure: Residual Refractive Cylinder
timeFrame: 6 Months post-surgery
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Alcon Call Center
state: Texas
Study officials:
References:
Clinical trial NCT03431116: Low Implanted Second Trimester Placenta and Placenta Previa
Official title: The Prediction of Risk Factors of Progression of Low Implanted Placenta at 18- 24 Weeks to Placenta Previa at Term
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Placenta Previa
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-02-13
Enrollment: 52
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: low implanted placenta women

Brief summary: Placenta Previa is defined as a placenta implanted in the lower segment of the uterus, presenting ahead of the leading pole of the fetus (over or near the internal os). The prevalence of placenta previa has been estimated to be approximately 0.5% of all pregnancies, and this increase correlates to the elevated cesarean section rate . In Egypt, the prevalence of placenta previa is around 1.3% in Sohag Governorate and 1.5% in Aswan region according to.

Although various studies have tried to address risk factors associated with Placenta Previa development, the etiology of placenta previa still remains obscure. Several risk actors have been identified as strong contributors to placenta previa development. It is also a significant contributor to severe postpartum hemorrhage.Risk factors include; history of previous cesarean section, advanced maternal age, history of previous abortions, high parity and substance abuse during pregnancy (cigarette smoking), placental size (multiple pregnancy), endometrial damage (previous dilatation and curettage), uterine scars and pathology (previous myomectomy or endometritis), placental pathology (marginal cord insertions and succenturiate lobes), previous placental Previa, and curiously.


Eligibility criteria: Inclusion Criteria:

1. Pregnant women between 18-24 weeks.
2. Diagnosed to have low implanted placenta by ultrasound

Exclusion Criteria:

1. Patient refused to follow-up in our setting.
2. Patient refused to perform Trans-vaginal ultrasound in the second trimester of gestation.

Primary outcomes:
measure: The distance between lower edge of the placenta and internal os by ultrasound (millimeter)
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women Health Hospital - Assiut university
Study officials:
References: